Market research
STAA STAAR Surgical Company
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 1B
- P/E ratio
- 289.25
- Analyst target
- 27.9
- Dividend yield
- Not available
- Beta
- 1.23
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- ISIN
- US8523123052
- Market cap
- 1B
- P/E ratio
- 289.25
- Analyst target
- 27.9
- Dividend yield
- Not available
- Beta
- 1.23
About
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, and sells phakic implantable lenses for the eye and accessory delivery systems to deliver the lenses into the eye. The company offers implantable collamer lens product family (ICLs) comprising EVO ICL, EVO+ ICL, EVO Visian ICL, and EVO Viva ICL for use in refractive surgery for the treatment of visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It serves health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as ophthalmologists. The company sells its products directly through its sales representatives in Japan, the United States, Germany, Spain, Singapore, Canada, and the United Kingdom, as well as through representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the STAA discussion.
5 years, 4 months ago
STAAR Surgical Company is currently in a long term uptrend where the price is trading 39.2% above its 200 day moving average.
From a valuation standpoint, the stock is 97.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 31.0.
STAAR Surgical Company's total revenue rose by 320.4% to $163M since the same quarter in the previous year.
Its net income has dropped by 7.3% to $6M since the same quarter in the previous year.
Finally, its free cash flow grew by 82.7% to $13M since the same quarter in the previous year.
Based on the above factors, STAAR Surgical Company gets an overall score of 4/5.